image: Dr. Ruben van Boxtel view more
Credit: Marloes Verweij, Laloes Fotografie
Van Boxtel says, ‘I am tremendously honored to have received the NYSCF Robertson Stem Cell Investigator award and grateful for this opportunity to accelerate my research.’ Van Boxtel's research focuses on unraveling the origins of late effects of treatment in children who had blood cancer and what role stem cells play in it. 'If we properly understand how these arise then that brings us a big step closer to finding a solution to prevent these effects. It also creates the possibility of predicting the likelihood of late effects prior to treatment and adjusting treatment accordingly.'
Follow-up on research leads
Research using cell cultures and mice provides insight into how stem cells can repair damaged tissues. Van Boxtel has also found possible leads for how this works in people by examining stem cells after chemotherapy in addition to transplanted stem cells. ‘Thanks to this award, we can continue this research. For example, we suspect, thanks to examining the blood system of chemotherapy-treated children, that some stem cells appear ‘stronger’ than other stem cells and are better able to generate new blood. It is therefore possible that ‘super stem cells’ exist. This would be an important discovery not only for the treatment of children with blood cancer, but also for many other diseases involving regenerative medicine using stem cells.
One and one is three
By winning the NYSCF Robertson Stem Cell Investigator Award, Van Boxtel joins a network of internationally prominent researchers in the field of stem cell biology and regenerative medicine. ‘Knowledge exchange and collaboration is crucial to achieving breakthroughs. It gives you new ideas because together you look at your research and outcomes from different perspectives. It is also enormously inspiring to combine knowledge and strengths with colleagues. This prize is therefore really a great accelerator and example of how one and one becomes three.’
Previously, Van Boxtel also received the ERC Consolidator grant and the Ammodo Science Award for groundbreaking research.
About late effects in survivors:
Children with cancer are often treated with chemotherapy at the Princess Máxima Center. In some cases, they also receive a stem cell transplant in addition. These forms of treatment have proven successful and on total average three out of four children are cured. However, an adverse consequence of these treatments is that not only are the cancer cells destroyed, but in some children healthy tissues are also damaged. This causes adverse late effects in these children later in life.
About Dr. Ruben van Boxtel:
Ruben van Boxtel has pioneered the development of experimental and computational approaches to study somatic mutations in healthy human stem cells. His group was the first to show how mutations accumulate in different tissues throughout human life and how this can contribute to cancer (Blokzijl et al., Nature 2016). In 2017, Ruben was appointed as a group leader at the Princess Máxima Center for Pediatric Oncology, where he focusses on studying why children can develop cancer and what the genotoxic effects of treatment are in normal tissues. Using in-depth mutational analyses, the group of Ruben has discovered mutational cancer signatures caused by a common gut bacterium (Pleguezuelos-Manzano et al., Nature 2020), antiviral drugs (de Kanter et al., Cell Stem Cell) or certain chemotherapeutic drugs (Bertrums et al., Cancer Discovery 2022).
Ruben has obtained several prestigious grants and awards for cancer and stem cell research from various organizations, such as the Netherlands Organization for Scientific Research (NWO) and the European Research Counsel (ERC), including the NWO VIDI (2017) and ERC Consolidator (2019) grants. In 2019, he was selected as an Oncode Investigator, which a collective institute bringing together the best fundamental cancer researchers in the Netherlands.
About the Princess Máxima Center for pediatric oncology
When a child is seriously ill from cancer, only one thing matters: a cure.
That is why at the Princess Máxima Center for pediatric oncology, we work together with passion, pushing the boundaries to improve survival and quality of life for children with cancer. Now, and in the long term. Because children have their entire lives ahead of them.
The Princess Máxima Center for pediatric oncology is no ordinary hospital but a research hospital, the biggest childhood cancer center in Europe. Here, more than 400 scientists and 900 healthcare professionals work closely with Dutch and international hospitals to find new treatments and new perspectives for a cure.
In this way, we offer children today the very best care, and take important steps toward improving survival for the children who are not yet cured.